Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients.

Integrative cancer science and therapeutics Pub Date : 2018-12-01 Epub Date: 2018-11-29 DOI:10.15761/ICST.1000293
Amanda Graul-Conroy, Margo Hoover-Regan, Kenneth B DeSantes, Paul M Sondel, Natalie S Callander, Walter L Longo, William E Fahl
{"title":"Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients.","authors":"Amanda Graul-Conroy,&nbsp;Margo Hoover-Regan,&nbsp;Kenneth B DeSantes,&nbsp;Paul M Sondel,&nbsp;Natalie S Callander,&nbsp;Walter L Longo,&nbsp;William E Fahl","doi":"10.15761/ICST.1000293","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models.</p><p><strong>Methods: </strong><i>A</i>drenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11-1 formulation) was orotopically applied to three patients (ages 24-29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide.</p><p><strong>Results: </strong>OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both \"Grade 3 OM\" duration and \"any OM\" duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients.</p><p><strong>Conclusion: </strong>Orotopically applied NG11-1 vasoconstrictor formulation substantially reduced the incidence and severity of \"Grade 3\" and \"any\" oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.</p>","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"5 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative cancer science and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ICST.1000293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models.

Methods: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11-1 formulation) was orotopically applied to three patients (ages 24-29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide.

Results: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both "Grade 3 OM" duration and "any OM" duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients.

Conclusion: Orotopically applied NG11-1 vasoconstrictor formulation substantially reduced the incidence and severity of "Grade 3" and "any" oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
局部血管收缩剂降低口腔黏膜炎严重程度:3例骨髓移植患者的病例报告。
背景:在>90%接受环磷酰胺+全身照射(CY+TBI)治疗方案的骨髓移植患者中,历史上观察到3级口腔黏膜炎(OM)。先前的研究表明,在两个临床前动物模型中,口腔局部应用肾上腺素能血管收缩剂可预防高达100%的放射性口腔黏膜炎。方法:将肾上腺素能血管收缩剂(即NG11-1水酒精制剂中的苯肾上腺素)应用于3例接受CY+TBI调理方案的患者(24-29岁);他们与未接受口腔局部血管收缩剂治疗的5名对照组进行了比较。在威斯康星大学成人骨髓移植项目中,所有患者接受急性淋巴细胞白血病CY+TBI调理方案。在为期7天的Cy+TBI调理方案中,每次放疗或化疗前20分钟,血管收缩剂局部应用于口腔,然后患者接受1.5 Gy全身放疗或静脉注射环磷酰胺。结果:在三周的时间内,使用以下方法对OM严重程度进行评分:i)身体评估,ii)口腔每日照片,iii)口腔疼痛和口腔功能评分表,iv)记录麻醉品消耗。血管收缩剂治疗患者的“3级OM”持续时间和“任何OM”持续时间均明显低于5名对照患者。虽然5例对照患者中有3例使用了鼻胃管或全肠外营养,但在3例血管收缩剂治疗的患者中没有使用这些支持护理措施。结论:与接受相同CY+TBI治疗方案的对照患者相比,口腔局部应用NG11-1血管收缩剂制剂可显著降低“3级”和“任何”口腔黏膜炎的发生率和严重程度。液体口腔外用制剂使用方便,无副作用,患者容易耐受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
APE1/Ref-1 with reducing activity induces mesenchymal-to-epithelial transition in TNF-α-stimulated breast cancer cells Exploiting mechanism-informed phenotypic screening for development of next-generation antimitotic phytochemicals Prospects for colorectal cancer prevention targeting intestinal microbiome Sclerosing Pneumocytoma: A Carcinoma Mimicker Phytotherapy and oncology. A short review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1